The
The order keeps a pause on a federal appeals court decision that would require patients to visit a provider in person to get a prescription for mifepristone. The new Supreme Court order lasts until May 14.
Louisiana is seeking to upend the
Mifepristone has been available by mail since 2021, when the FDA said it would stop enforcing the in-person rule because of the pandemic. The FDA formally lifted the requirement in 2023.
The clash has threatened to upend abortion access nationwide. Pill-induced abortions accounted for 63% of all abortions in 2023, and mifepristone was used in the vast majority of cases, according to the Guttmacher Institute, a research organization that supports reproductive rights. Louisiana and other states with abortion bans say remote prescriptions are undermining those laws.
The drug’s manufacturers,
The cases are Danco v. Louisiana, 25a1207, and GenBioPro v. Louisiana, 25a1208.
© 2026 Bloomberg L.P. All rights reserved. Used with permission.
To contact the reporter on this story:
To contact the editors responsible for this story:
Greg Stohr
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.